We already have a follow-up story on targeting avapritinib with MAP kinase inhibitors that we are just as excited about." ...

This early data suggests that avapritinib is generally safe and may trigger an initial clinical response in a small group of patients who have pediatric high-grade gliomas with PDGFRA amplification.